Lack of Clinical Usefulness of Das-1 Monoclonal Antibody and Mucin Expression as Risk Markers of Gastric Carcinoma in Patients With Gastric Intestinal Metaplasia

    loading  Checking for direct PDF access through Ovid


Our aim was to evaluate the usefulness of the monoclonal antibody Das-1 as a premalignant marker of gastric intestinal metaplasia (GIM) associated with gastric cancer and its association with mucin expression.

We evaluated Das-1 and mucin expression in 4 groups: 1 (n = 50), gastric carcinoma, paired samples of the cancer area and GIM away from the tumor; 2 (n = 25), gastric or duodenal ulcer with Helicobacter pylori infection with GIM and chronic gastritis; 3 (n = 25), H pylori–autoimmune chronic atrophic gastritis with GIM; and 4 (n = 25), H pylori–chronic gastritis without GIM.

Das-1 immunostaining was observed in 20 (40%) of 50 cases in cancer areas. The expression of Das-1 in GIM from group 1 cases away from the cancer area was different from that in GIM from nontumor cases (groups 2 and 3): 13 (26%) of 50 vs 2 (8%) and 0 (0%) of 25 (P = .004). There was no association between Das-1 and mucin expression.

Das-1 expression was associated with GIM from patients with gastric cancer. However, this relation was weaker than previously reported, precluding clinical usefulness as a premalignant marker of GIM.

Related Topics

    loading  Loading Related Articles